SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
SBTX Stock Chart & Stats
13.25 p
-0.88 p(-5.43%)
At close: 4:00 PM EST
13.25 p
-0.88 p(-5.43%)
Day’s Range― - ―
52-Week Range5.00 p - 27.50 p
Previous CloseN/A
Volume282.34K
Average Volume (3M)673.17K
Market Cap
£25.27M
Enterprise Value21.48M
Total Cash (Recent Filing)£4.78M
Total Debt (Recent Filing)£993.47K
Price to Earnings (P/E)32.2
Beta0.25
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)£6.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth indicates strong top-line momentum and customer uptake of the company’s products. Over 2-6 months this growth supports scaling prospects, strengthens negotiation leverage with partners, and provides a foundation to expand manufacturing and distribution if margins and cash conversion improve.
Conservative Balance SheetLow leverage and a healthy equity ratio reduce refinancing and liquidity risk, giving management flexibility to fund R&D, commercialisation or partnerships without immediate pressure. This conservatism supports operational resilience through near-term product rollouts or regulatory steps.
Niche Technology & Market FocusA science-driven focus on microbiome and probiotic skin health targets growing structural demand in dermatology and cosmetics. This differentiated platform can enable multiple durable revenue streams (direct products, licensing, supply) and creates higher barriers for commodity competitors over coming months.
Bears Say
Ongoing UnprofitabilityPersistent negative EBIT and net income mean the business is not yet generating operating profits from sales. Over the next 2-6 months this limits internal reinvestment, raises dependence on external funding, and constrains the ability to scale supply chains or larger commercial initiatives without dilutive financing.
Weak Cash GenerationNegative operating and free cash flows indicate the company consumes cash to run and grow its business. This structural cash deficit increases fundraising frequency, restricts marketing/manufacturing spend, and heightens execution risk on product rollouts and partnership commitments over the medium term.
Negative Return On EquityA negative ROE shows capital currently deployed is not producing shareholder returns. This signals inefficiency in turning R&D and commercial investment into profit, which could pressure management to alter strategy or seek additional capital, affecting long-term dilution and execution choices.
SkinBioTherapeutics News
SBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 5.00 p and its highest was 27.50 p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £25.27M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 01, 2026 which is in 241 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
Currently, no data Available
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―